A complementary approach to treating antibody-mediated transplant rejection

Peter S. Heeger

Research output: Contribution to journalComment/debate

4 Scopus citations


Current treatment for antibody-mediated kidney transplant rejection is inadequate. Tillou and colleagues administered recombinant C1 inhibitor to block complement activation to prevent antibody-initiated injury in sensitized baboon recipients of kidney allografts. These early but encouraging results support further testing of the safety and efficacy of complement inhibition as part of a comprehensive strategy to treat this disease, both in animal models and ultimately in humans.

Original languageEnglish
Pages (from-to)125-127
Number of pages3
JournalKidney International
Issue number2
StatePublished - Jul 2010


Dive into the research topics of 'A complementary approach to treating antibody-mediated transplant rejection'. Together they form a unique fingerprint.

Cite this